LIXT - Lixte Biotechnology starts enrollment in early-stage lung cancer study

Lixte Biotechnology Holdings ([[LIXT]] -0.7%) announces the enrollment of the first patient in a Phase 1b clinical trial to assess the combination of LB-100 with a standard regimen for previously untreated, extensive stage-disease small cell lung cancer ((ED-SCLC)).The trial for LB-100, which is Lixte’s first-in-class protein phosphatase 2A (PP2A) inhibitor, is being conducted with City of Hope, an independent cancer research and treatment center. In the trial, LB-100 will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC.The dose of LB-100 will be escalated with fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose ((RP2D)).

For further details see:

Lixte Biotechnology starts enrollment in early-stage lung cancer study